Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis

Abstract

Multiple sclerosis is a heterogeneous neurological disease with varying degrees of severity. The common hypothesis is that susceptibility to multiple sclerosis and its phenotype are caused by a combination of environmental and genetic factors. The genetic part exerts its effect through several genes, each having modest effects.

We evaluated whether disease severity could be predicted by a model based on clinical data and data from a DNA chip. The DNA chip was designed containing several single nucleotide polymorphisms in 44 genes, previously described to be associated with multiple sclerosis.

A total of 605 patients with multiple sclerosis were included in this analysis, using gender, onset type and age at onset as clinical covariates. We correlated 80 single nucleotide polymorphisms to the degree of disease severity using the following three outcome measures: linear Multiple Sclerosis Severity Score, dichotomous Multiple Sclerosis Severity Score (using a cut-off point of 2.5) and time to reach Expanded Disability Status Scale score 6.

Sixty-nine single nucleotide polymorphisms were included in the analysis. No individual single nucleotide polymorphism showed a significant association; however, a combination of single nucleotide polymorphisms significantly improved the prediction of disease severity in addition to the clinical variables. In all three models the Interleukin 2 gene was included, confirming a previously reported modest effect on disease severity. The highest power was obtained using the dichotomized Multiple Sclerosis Severity Score as outcome.

Several single nucleotide polymorphisms showed their added predictive value over the clinical data in the predictive models. These results support our hypothesis that disease severity is determined by clinical variables and genetic influences (through several genes with small effects) in concert.

Keywords

genetics multiple sclerosis outcome Interleukin 2

Get full access to this article

View all access options for this article.

References

Compston A. , Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.

Gregory SG , Schmidt S. , Seth P. , et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083-1091.

Hafler DA , Compston A. , Sawcer S. , et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.

Lundmark F. , Duvefelt K. , Iacobaeus E. , et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007 ; 39: 1108-1113.

De Jager PL , Jia X. , Wang J. , et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.

Frohman EM , Filippi M. , Stuve O. , et al. Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions. Arch Neurol 2005; 62: 1345-1356.

Doolittle TH , Myers RH , Lehrich JR , et al. Multiple sclerosis sibling pairs: Clustered onset and familial predisposition. Neurology 1990; 40: 1546-1552.

Bulman DE , Sadovnick AD , Ebers GC Age of onset in siblings concordant for multiple sclerosis. Brain 1991; 114: 937-950.

Brassat D. , Azais-Vuillemin C. , Yaouanq J. , et al. Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group. Neurology 1999; 52: 1632-1636.

10.

Barcellos LF , Oksenberg JR , Green AJ , et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; 125: 150-158.

11.

Hensiek AE , Seaman SR , Barcellos LF , et al. Familial effects on the clinical course of multiple sclerosis . Neurology 2007; 68: 376-383.

12.

Kantarci OH , de Andrade M. , Weinshenker BG Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002; 123: 144-159.

13.

Ramagopalan SV , DeLuca GC , Degenhardt A. , Ebers GC The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008; 201-202: 183-199.

14.

Ramagopalan SV , DeLuca GC , Morrison KM , et al. Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis. J Neurol 2008; 255: 1215-1219.

15.

DeLuca GC , Ramagopalan SV , Herrera BM , et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007 ; 104: 20896-20901.

16.

Barcellos LF , Oksenberg JR , Begovich AB , et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710-716.

17.

Hoffmann S. , Cepok S. , Grummel V. , et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83: 219-227.

18.

Okuda DT , Srinivasan R. , Oksenberg JR , et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures . Brain 2009; 132: 250-259.

19.

Sombekke MH , Lukas C. , Crusius JB , et al. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Arch Neurol 2009; 66: 1531-1536.

20.

Polman CH , Reingold SC , Edan G. , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald Criteria’’. Ann Neurol 2005; 58: 840-846.

21.

Poser CM , Paty DW , Scheinberg L. , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.

22.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.

23.

Roxburgh RH , Seaman SR , Masterman T. , et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.

24.

Tejedor D. , Castillo S. , Mozas P. , et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005; 51: 1137-1144.

25.

Benjamini Y. , Hockberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.

26.

DeLong ER , DeLong DM , Clarke-Pearson DL Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.

27.

van Houwelingen JC , Le Cessie S. Predictive value of statistical models. Stat Med 1990; 9: 1303-1325.

28.

Horak I. , Lohler J. , Ma A. , Smith KA Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance . Immunol Rev 1995; 148: 35-44.

29.

Maier LM , Wicker LS Genetic susceptibility to type 1 diabetes. Curr Opin Immunol 2005; 17: 601-608.

30.

Schimpl A. , Berberich I. , Kneitz B. , et al. IL-2 and autoimmune disease. Cytokine Growth Factor Rev 2002; 13: 369-378.

31.

Matesanz F. , Fedetz M. , Collado-Romero M. , et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol 2001; 119: 101-105.

32.

Fedetz M. , Ndagire D. , Fernandez O. , et al. Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population. Tissue Antigens 2009; 74: 244-247.

33.

Rose JW , Burns JB , Bjorklund J. , Klein J. , Watt HE , Carlson NG Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-789.

34.

Killestein J. , Den Drijver BF , Van der Graaff WL , Uitdehaag BM , Polman CH , Van Lier RA Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler 2001; 7: 145-150.

35.

Baranzini SE , Wang J. , Gibson RA , et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2008; 18: 767-778.

36.

Fisniku LK , Brex PA , Altmann DR , et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-817.